CorMedix Inc. Segments Disclosure
Note 12 - Segment Reporting
The Company has determined that it has one reportable segment- Drug Product primarily sold in the United States with contract revenue consisting of BARDA in the US and product, royalty and milestone revenues outside of the US.
The Company’s is the Chief Operating Decision Maker (“CODM”). The CODM manages the Company’s business activities as a single reportable segment. The CODM uses consolidated profit and loss to evaluate and measure performance against progress in its commercialization efforts and clinical trials. The following table sets forth significant segment expenses.
| Year Ended December 31, | ||||||||
| 2025 | 2024 | |||||||
| Research and development: | ||||||||
| Employee expense | $ | 7,756 | $ | 2,455 | ||||
| Other research and development | 11,577 | 1,487 | ||||||
| Total research and development | 19,333 | 3,942 | ||||||
| Selling and marketing | ||||||||
| Employee and contracted employee expense | $ | 22,618 | $ | 13,494 | ||||
| Other selling and marketing | 15,436 | 15,243 | ||||||
| Total selling and marketing expense | 38,054 | 28,737 | ||||||
| General and administrative | ||||||||
| Employee expense | $ | 32,584 | $ | 18,321 | ||||
| Other general and administrative | 35,636 | 11,638 | ||||||
| Total general and administrative expense | 68,220 | 29,959 | ||||||
| Total operating expenses | $ | 125,607 | $ | 62,638 | ||||
The CODM also reviews DefenCath sales separately from sales from the Melinta Portfolio; the following table sets forth the breakdown of sales:
| Year Ended December 31, | ||||||||
| 2025 | 2024 | |||||||
| Product Sales: | ||||||||
| DefenCath | $ | 258,813 | $ | 43,472 | ||||
| Melinta Portfolio | 45,531 | |||||||
| Total product sales | 304,344 | 43,472 | ||||||
| Contract Revenue | 7,365 | |||||||
| Total Revenues | 311,709 | 43,472 | ||||||
Want the next CorMedix Inc. segments disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment CorMedix Inc.'s next filing hits EDGAR. No credit card, your email never gets sold.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 5, 2026 | Showing above |
| 2024 | Mar 25, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.